Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lysogene Appoints Chief Scientific Officer

Executive Summary

Lysogene, a biotech company specialising in the treatment of central nervous system diseases, has appointed Kimberley S. Gannon chief scientific officer. Gannon joins the business from NeuroPhage Pharmaceuticals Inc., where she was senior vice president of preclinical research and development. Prior to this, she held several leadership positions at other companies, including vice president of research and development at CereMedix, and senior director of biology at EPIX (Predix) Pharmaceuticals. Her expertise spans preclinical pharmacology, translational medicine and nonclinical drug development.

You may also be interested in...



Coronavirus Update: Lilly’s Antibody Plus Remdesivir Trial Abandoned

Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.

Coronavirus Update: AstraZeneca’s Vaccine Trials Cleared To Restart In the US, J&J Prepares To Restart Its Vaccine Study

Two potential COVID-19 vaccine trials from AstraZeneca and Johnson & Johnson are set to resume in the US following temporary pauses due to safety concerns. Data from both could come later this year.

Coronavirus Update: Gilead's Veklury Gets Full FDA Approval, Roche Partners With Atea

Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine. 

Topics

UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel